Clinical Trial Update: PTCy and Ruxolitinib GVHD Prophylaxis in Myelofibrosis [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluated prophylaxis for graft-versus-host disease using post-transplant cyclophosphamide and ruxolitinib in patients with primary m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Myeloproliferative Disorders

Drugs mentioned

• Ruxolitinib (ruxolitinib)
• post-transplant cyclophosphamide (cyclophosphamide)

Snippet

Sponsor: St. Petersburg State Pavlov Medical University | Conditions: Primary Myelofibrosis, Myeloproliferative Disorders | Phase 1, Phase 2 | Status: COMPLETED